Targeted use of antiresorptives and osteoanabolic agents and avoid “rebound” effects

Postmenopausal osteoporosis in women is a consequence of decreasing oestrogen levels and is associated with rapid bone loss (“high-turnover osteoporosis”). Long-term therapy concepts are required to achieve sustainable effects – if osteoporosis medication is discontinued without follow-up treatment, the osteoprotective effect is lost and there is a risk of renewed bone density loss. Sequential treatment strategies are therefore crucial to prevent rebound effects.